pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,652 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive241onclive165Fierce Biotech91BioSpace90raps32globenewswire health28fda recalls
therapy area
allOncology574Rare Disease284Immunology229Cardiology193Hematology159Pulmonology131Vaccines99
  • Imaging Clues That Raise Suspicion for Diffuse Midline Glioma
    n this episode, Dr. Chong sets up the clinical reality that patients usually present with imaging before tissue and asks Dr. Shonka how MRI findings should shape suspicion for DMG.
    onclive · 2mo ago↗ source
  • Two Diseases That Share a Name — Defining Glioblastoma and Diffuse Midline Glioma Under the 2021 WHO Classification
    In this opening episode, Dr. Shonka and Dr. Chong frame the conversation around two diseases that share the name glioma but differ fundamentally in biology, demographics, and treatment.
    onclive · 2mo ago↗ source
  • STAT+: CDC plans to transfer monkeys to nonprofit’s sanctuary as it seeks to reduce animal testing
    The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas, as the agency seeks to phase out…
← prev
page 45 of 67
next →
22
fda press21
fda medwatch17
Psychiatry & CNS87
Ophthalmology86
Pain75
Endocrinology & Metabolism52
Dermatology51
STAT · 2mo ago↗ source
  • Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance
    Aaron Gerds, MD, MS, and Anthony M. Hunter, MD, break down the challenges of anemia management in myelofibrosis and potential treatment avenues.
    onclive · 2mo ago↗ source
  • STAT+: The hunt for FDA’s next leader
    Marty Makary is out, and the Trump administration has a long wish list for its next FDA commissioner.
    STAT · 2mo ago↗ source
  • STAT+: MIT says research has fallen 10%, and grad student enrollment is down
    At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.
    STAT · 2mo ago↗ source
  • Perioperative Durvalumab Plus Neoadjuvant EV Displays EFS, OS Benefits vs SOC in MIBC
    Perioperative durvalumab plus EV showed positive topline efficacy findings in MIBC.
    onclive · 2mo ago↗ source
  • Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer
    The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.
    onclive · 2mo ago↗ source
  • Drugmakers have to go through rigorous tests to get a lower tariff rate
    Landing a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald Trump signed an executive or…
    Endpoints · 2mo ago↗ source
  • Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last Decade
    A Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.
    onclive · 2mo ago↗ source
  • Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data
    💸 A Series A extension: US-China biotech Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform. The San Diego and Shanghai biotech has raised $95 mil…
    Endpoints · 2mo ago↗ source
  • REVELUTION-2 Trial Is Evaluating Cardiovascular Risk With Relugolix Plus Abiraterone Acetate in High-Risk Prostate Cancer
    Sagar A. Patel, MD, discusses the REVELUTION-2 trial evaluating cardiovascular safety with hormone therapy in prostate cancer.
    onclive · 2mo ago↗ source
  • AstraZeneca follows Merck with Phase 3 win in bladder cancer
    A combination of AstraZeneca's Imfinzi with Pfizer and Astellas’ Padcev kept more bladder cancer patients alive than standard of care, the company said Thursday. AstraZeneca said it would seek appr…
    Endpoints · 2mo ago↗ source
  • STAT+: BeOne wins FDA approval in lymphoma race
    Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
    STAT · 2mo ago↗ source
  • MacroGenics sells manufacturing arm; West Pharma discloses cybersecurity attack
    Plus, news about Bavarian Nordic and OrganaBio’s new CDMO subsidiary: 🏭 Bora buys MacroGenics' manufacturing operations: MacroGenics is selling its clinical and commercial drug substance productio…
    Endpoints · 2mo ago↗ source
  • STAT+: Why big digital health players are missing from Medicare’s chronic care experiment
    In this edition of STAT Health Tech: Why big digital health players skipped Medicare's ACCESS pilot, Isomorphic's big raise, and more.
    STAT · 2mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more
    Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau
    STAT · 2mo ago↗ source
  • Clinical Implementation and Surveillance Strategies
    onclive · 2mo ago↗ source
  • Case Introduction and ctDNA as Emerging Risk Factor
    onclive · 2mo ago↗ source
  • How Penn Medicine plans to use AI to train their doctors
    Physicians at Penn Medicine said they're thinking of how to use AI to train doctors. The idea came out of a $1.1 million grant Penn Medicine won in January through an education grant program with ...
    Endpoints · 2mo ago↗ source
  • ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies
    Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.
    onclive · 2mo ago↗ source
  • MET Alterations in NSCLC: Amplification, Mutations, and Therapeutic Strategies
    Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.
    onclive · 2mo ago↗ source
  • Planned HERIZON-GEA-01 Analyses and the Doublet-vs-Triplet Question
    New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.
    onclive · 2mo ago↗ source
  • HERIZON-GEA-01 Efficacy Results and Interpretation of Duration of Response
    HORIZON-GA01 shows zenidatamab regimens significantly improve survival in HER2-positive gastric cancer, while PD-L1 testing differences raise key questions for treatment choice.
    onclive · 2mo ago↗ source
  • Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial (CT029)
    Five-year Phase III data show tebentafusp doubles survival in metastatic uveal melanoma, with ctDNA response predicting benefit beyond imaging and progression.
    onclive · 2mo ago↗ source